je.st
news
Home
› CHMP Issues Positive Opinion for Intravenous (IV) Formulation of Mercks NOXAFIL (posaconazole)
CHMP Issues Positive Opinion for Intravenous (IV) Formulation of Mercks NOXAFIL (posaconazole)
2014-07-30 14:00:03| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J., July 30, 2014 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new, investigational intravenous (IV) formulation of NOXAFIL (posaconazole). Language: English read more
Tags: issues
positive
opinion
formulation
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||